U.S. markets closed
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • Dow 30

    34,580.08
    -59.71 (-0.17%)
     
  • Nasdaq

    15,085.47
    -295.85 (-1.92%)
     
  • Russell 2000

    2,159.31
    -47.02 (-2.13%)
     
  • Crude Oil

    66.22
    -0.28 (-0.42%)
     
  • Gold

    1,782.10
    +21.40 (+1.22%)
     
  • Silver

    22.45
    +0.17 (+0.76%)
     
  • EUR/USD

    1.1317
    +0.0012 (+0.10%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • GBP/USD

    1.3235
    -0.0067 (-0.50%)
     
  • USD/JPY

    112.8000
    -0.4090 (-0.36%)
     
  • BTC-USD

    52,889.84
    -3,522.92 (-6.24%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Neuronetics' NeuroStar Mental Health Therapy Shows Better Safety Over H-Coil TMS

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Neuronetics Inc (NASDAQ: STIM) has announced that a peer-reviewed paper showed significantly lower seizure risk with NeuroStar Advanced Therapy for Mental Health than with TMS treatments that claim deeper stimulation with H-Coil technology.

  • The journal surveyed approximately 500 members of the Clinical TMS Society (CTMSS) about seizures in their practice.

  • A total of 125 surveys were evaluated, which included 586,656 TMS treatment sessions.

  • "While the overall occurrence of seizures with all TMS treatments is low, this study showed that the real-world risk for seizure was 52 to 90 times higher with H-coil TMS treatment than with NeuroStar treatment," stated Cory Anderson, VP, Clinical Affairs & Interim VP, R&D, Neuronetics.

  • NeuroStar, an advanced therapy system, is a transcranial magnetic stimulation (TMS) treatment for major depressive disorder in adults, with over four million treatments delivered.

  • Read Next: Neuronetics Stock Plunges As Q2 Earnings Miss Expectations; Underwhelming Q3 Revenue Outlook.

  • Price Action: STIM stock is down 2.61% at $6.35 during the market session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.